Medindia LOGIN REGISTER
Medindia
Advertisement

Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board

Friday, September 14, 2007 General News
Advertisement
AMSTERDAM, September 13 Agendia BV, a world leader in therapidly evolving field of cancer molecular diagnostics, announced today thatit has appointed Hessel J. H. M. Lindenbergh as Chairman of its SupervisoryBoard.
Advertisement

Hessel Lindenbergh is a former member of the managing board of ING GroupN.V.. Currently, Mr. Lindenbergh is chairman of the supervisory board of NIBCapital N.V. and board member of the Royal Numico, Petroplus Internationaland Gamma Holding. Mr. Lindenbergh is also a member of the board of directorsof the University of Amsterdam (UvA) and Senior Counsel at the Boer & Croon.
Advertisement

Agendia's other supervisory board directors are Prof. Dr. Wim van Hartenfrom the Netherland's Cancer Institute (NKI), Pieter van der Meer from GildeHealth Care, Gertjan van der Baan from van Herk Biotech B.V., and Dr. GosseBruisma, an independent member.

In making this announcement, Agendia's CEO, Dr. Bernhard Sixt, stated:"We are very pleased that Mr. Hessel Lindenbergh has accepted the chair ofthe company's Supervisory Board bringing along a tremendous internationalreputation in the financial business. We are convinced that our SupervisoryBoard will contribute to further build the company strategically and toaccelerate the commercial success of Agendia."

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in geneexpression analysis-based diagnostics with three products on the market. Thecompany focuses on the development and commercialization of diagnostic testsusing tumor gene expression profiling. Agendia was the first company tocommercialize a prognostic test - MammaPrint(R) - that predicts the risk ofbreast cancer recurrence. Its second microarray product, CupPrint(R)(i), is adiagnostic test to identify the origin of a metastasis in a cancer typecalled "Cancer of Unknown Primary". Agendia recently also presented its newcolon cancer prognosis profile, ColoPrint(R), which is currently undergoingfurther validation.

Agendia maintains close ties with several leading academic centers todevelop state of the art diagnostic tests for cancer. Agendia also offers itsexpertise to pharma companies focusing on development of highly effectivepersonalized drugs in the area of oncology.

(i) CupPrint(R) is based on a license to the TUA database of AviaraDx

(ii) RNAretain(R) is a trademark of Asuragen Inc.

SOURCE Agendia BV
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close